Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: coronavirus neutralising antibodies - AbCellera/Eli Lilly and Company

Drug Profile

Research programme: coronavirus neutralising antibodies - AbCellera/Eli Lilly and Company

Alternative Names: coronavirus (2019-nCoV) neutralising antibodies - AbCellera/Eli Lilly and Company; SARS-CoV-2-neutralizing antibodies - AbCellera/Eli Lilly and Company

Latest Information Update: 07 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abcellera; Eli Lilly and Company
  • Developer Abcellera; Eli Lilly and Company; National Institute of Allergy and Infectious Diseases
  • Class Antibodies; Antivirals
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 01 Jul 2020 Sanford Burnham Prebys Medical Discovery Institute enters into an research agreement with Eli Lilly and Company to characterise Lilly’s next-generation anti-SARS-CoV-2 antibodies
  • 08 Jun 2020 AbCellera in-licenses ISPRI from EpiVax
  • 12 Mar 2020 Abcellera and Eli lilly and Company agree co-develop Coronavirus neutralizing antibodies in Canada for COVID-19 infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top